ChemicalBook > Product Catalog >API >Antineoplastic agents >Natural sources of antineoplastic >Paclitaxel

Paclitaxel

Paclitaxel is a monomer diterpenoid compound extracted from bark of the natural plant, taxus. It is a kind of complex secondary metabolites and is currently known as the only kind drug that can promote microtubule polymerization and stabilize polymerized microtubules. Isotopic tracing has showed that paclitaxel only binds to polymerized microtubules without reacting with the non-polymerized tubulin dimer.
Paclitaxel Suppliers list
Company Name: Nanjing Gold Pharmaceutical Technology Co. Ltd.
Tel: 025-84209270 15906146951
Email: wgp@nanjing-pharmaceutical.com
Products Intro: Product Name:Paclitaxel
CAS:33069-62-4
Purity:99% Package:50KG;25KG;10KG;5KG;1KG
Company Name: Shenzhen Sendi Biotechnology Co.Ltd.
Tel: 0755-23311925 18102838259
Email: Abel@chembj.com
Products Intro: Product Name:Paclitaxel
CAS:33069-62-4
Purity:99% Package:170000/KG
Company Name: Frapp's ChemicalNFTZ Co., Ltd.
Tel: +86 (576) 8169-6106
Email: sales@frappschem.com
Products Intro: Product Name:Paclitaxel
CAS:33069-62-4
Company Name: Beijing Zhongshuo Pharmaceutical Technology Development Co., Ltd  Gold
Tel:010-64430626/13801208576
Email:maggie@chinazhongshuo.com
Products Intro:Product Name:Paclitaxel (Natural/Semi-Synthetic)
CAS:33069-62-4
Purity:99%
Company Name: Guangzhou Isun Pharmaceutical Co., Ltd  Gold
Tel:020-39119399 18927568969
Email:isunpharm@qq.com, isunpharm@hotmail.com
Products Intro:Product Name:Paclitaxel
CAS:33069-62-4
Purity:>98% Package:1g;5g;50g;500g;5kg;25kg
Paclitaxel Basic information
Indications and Usage Mechanisms of Action Warnings and Precautions
Product Name:Paclitaxel
Synonyms:Paclitaxel HCL;Paclitaxel(natural crude);αR-hydroxy-βS-(benzoylamino)-benzenepropanoic acid, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester;Paclitaxel, Antibiotic for Culture Media Use Only;Paclitaxelx;N-BENZYL-BETA-PHENYLISOSERINE ESTER;PACLITAXEL, TAXUS BREVIFOLIA;PACLITAXEL, TAXUS SPECIES
CAS:33069-62-4
MF:C47H51NO14
MW:853.91
EINECS:205-285-7
Product Categories:Inhibitors;Active Pharmaceutical Ingredients;Pharmaceutical material and intermeidates;Antineoplastics;Antineoplastic;APIs;Antitumors for Research and Experimental Use;Biochemistry;Natural Plant Extract;Intermediates & Fine Chemicals;Pharmaceuticals;Natural Anti-cancer Medical Materials and It's Derivatives;Antitumour;Signalling;Aromatics;Chiral Reagents;Heterocycles;Plant extract;API;Plant extracts;chemical reagent;pharmaceutical intermediate;phytochemical;reference standards from Chinese medicinal herbs (TCM).;standardized herbal extract;CLOBEX;Isolabel;antibiotic;Anti-cancer&immunity
Mol File:33069-62-4.mol
Paclitaxel Structure
Paclitaxel Chemical Properties
Melting point 213 °C (dec.)(lit.)
density 0.200
refractive index -49 ° (C=1, MeOH)
Fp 9℃
storage temp. 2-8°C
solubility methanol: 50 mg/mL, clear, colorless
form powder
color white
Merck 6982
Stability:Stable. Incompatible with strong oxidizing agents. Combustible.
CAS DataBase Reference33069-62-4(CAS DataBase Reference)
EPA Substance Registry SystemBenzenepropanoic acid, .beta.-(benzoylamino)-.alpha.- hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S, 12aR,12bS)-6,12b-bis(acetyloxy)- 12-(benzoyloxy)-2a,3,4,4a, 5,6,9,10,11,12,12a,12b-dodecahydro- 4,11-dihydroxy-4a,8,13,13- tetramethyl-5-oxo-7,11-methano- 1H-cyclodeca[3,4]benz[1,2- b]oxet-9-yl ester, (.alpha.R,.beta.S)-(33069-62-4)
Safety Information
Hazard Codes Xn
Risk Statements 37/38-41-42/43-62-68-40-48-20/21/22-68/20/21/22
Safety Statements 22-26-36/37/39-45
RIDADR 1544
WGK Germany 3
RTECS DA8340700
10-21
HazardClass 6.1(b)
PackingGroup III
Hazardous Substances Data33069-62-4(Hazardous Substances Data)
MSDS Information
ProviderLanguage
Paclitaxel English
SigmaAldrich English
ACROS English
Paclitaxel Usage And Synthesis
Indications and UsagePaclitaxel is a monomeric diterpene compound extracted from Chinese yew bark and is a complicated secondary metabolite. Stage II-III clinical studies show that paclitaxel is most suitable for ovarian and breast cancer, and has certain efficacy in treating prostate cancer, lung cancer, colorectal cancer, melanoma, head and neck cancer, esophageal cancer, germ cell tumors, endometrial cancer, lymphoma, brain tumors, bladder cancer, upper gastrointestinal cancer, small cell and non-small cell lung cancer.
Mechanisms of ActionPaclitaxel is currently the only known drug that can promote microtubule polymerization and stabilize polymerized microtubules. It can only form on polymerized microtubules and does not react with non-polymerized microtubule protein dipolymers. After coming in contact with paclitaxel, cells will accumulate a large number of microtubules within themselves, which disrupts cell functions, especially cell division, which is forced to cease at the mitotic stage.
Warnings and Precautions1. Hermatological toxicity: the main factor in increased dosage limitations; when white blood cells are below 1500/mm3, supplement with G-CSF; when platelets are below 30000/mm3, transfuse component blood.
2. Allergic reaction: Aside from preconditions, if there are only minor symptoms such as flushed face, skin reactions, slightly increase heart rate, slightly lowered blood pressure, etc., do not stop treatment and decrease injection speed. If there are serious reactions such as hypotension, vascular edema, difficulty breathing, measles, etc., stop treatment and treat accordingly. Patients with serious allergic reactions should not use paclitaxel in the future.
3. Nervous system: Common reactions include numb toes. Approximately 4% patients, especially with high dosage, experience significant sensory and motor difficulty and decreased tendon reflex. There have been individual reports of epilepsy.
4. Cardiovascular: Transient tachycardia and hypotension are common and do not usually require attention. However, monitor closely during first hour of injection. Afterwards, only patients with serious injection difficulty require hourly check-ins.
5. Join and muscle: Approximately half of the patients will experience some joint and muscle pain within the first 2-3 days following injection, which is related to dosage, and usually subsides after a couple days. Patients who are also administered G-CSF will experience heightened muscle pain.
6. Liver and gall: As paclitaxel is mainly excreted through bile, patients with liver and gall diseases must be monitored carefully. Among thousands of cases, 8% of patients experienced increased bilirubin, 23% experienced increased alkaline phosphatase, and 18% experienced increased glutamic-oxalacetic transaminase. However, there is currently no evidence indicating that paclitaxel causes any severe liver damage.
7. Other: Digestive tract reactions are common but rarely severe, with few cases of diarrhea and mucosa infection. Slight alopecia is also common.
Chemical PropertiesWhite Powder
Usesglucocorticoid, antiinflammatory
UsesAn antineoplastic. Used in the study of structure and function of microtubles into tubulin. Paclitaxel is now used to treat patients with lung, ovarian, breast cancer, head and neck cancer, and advanc ed forms of Kaposi's sarcoma. Paclitaxel is a mitotic inhibitor used in cancer chemotherapy.
General DescriptionNeedles (from aqueous methanol) or fine white powder. An anti-cancer drug.
Air & Water ReactionsMay be sensitive to prolonged exposure to moisture. .
Health HazardTOXIC; inhalation, ingestion or skin contact with material may cause severe injury or death. Contact with molten substance may cause severe burns to skin and eyes. Avoid any skin contact. Effects of contact or inhalation may be delayed. Fire may produce irritating, corrosive and/or toxic gases. Runoff from fire control or dilution water may be corrosive and/or toxic and cause pollution.
Fire HazardFlash point data for Paclitaxel are not available. Paclitaxel is probably combustible.
Biological ActivityAntitumor agent; promotes and stabilizes tubulin polymerization, causing cell cycle arrest. Induces autocatalytic activation of caspase-10 in CCRF-HSB-2 cells, triggering apoptosis.
Paclitaxel Preparation Products And Raw materials
Raw materialsEthyl acetate-->Silica gel-->Celite
Tag:Paclitaxel(33069-62-4) Related Product Information
Irinotecan Irinotecan hydrochloride polyglutamic acid-paclitaxel PACLITAXEL SOLUTION STD 0.5mg/mL(P) paclitaxel-transferrin (-)-Paclitaxel-2''-hemisuccinate 6a-Hydroxy Paclitaxel-d5 SIDE CHAINS OF PACLITAXEL--3 poly(ethylene glycol)-conjugated paclitaxel-2'-glycinate XYLOSYLTAXOL PACLITAXEL-[BENZOATE RING-UL-14C] 7-(2',3''-DIHYDROXYPROPYL CARBONOXY)PACLITAXEL 6a-Hydroxy Paclitaxel PACLITAXEL C13 LABELED PACLITAXEL, [2-BENZOYL RING-14C(U)] PACLITAXEL-D5 3'-P-HYDROXYTAXOL XYLOSYLTAXOL, 7